Page last updated: 2024-12-08

nsc 348884

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

NSC 348884: a nucleophosmin inhibitor with antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID335974
CHEMBL ID4584341
SCHEMBL ID12126212
MeSH IDM0523734

Synonyms (27)

Synonym
nsc348884
n,n',n'-tetrakis[(6-methyl-1h-benzimidazol-2-yl)methyl]ethane-1,2-diamine
81624-55-7
nsc-348884
n,n,n',n'-tetrakis[(6-methyl-1h-benzimidazol-2-yl)methyl]ethane-1,2-diamine
BCP9000996
nsc348884 hydrate
LP01178
S8149
SCHEMBL12126212
n,n,n',n'-tetrakis-(5-methyl-1h-benzoimidazol-2-ylmethyl)-ethane-1,2-diamine
nsc 348884
AC-32976
DTXSID90319638
CS-5564
HY-13915
AKOS027439888
(2-{bis[(6-methyl-1h-1,3-benzodiazol-2-yl)methyl]amino}ethyl)bis[(6-methyl-1h-1,3-benzodiazol-2-yl)methyl]amine
n1,n1,n2,n2-tetrakis((6-methyl-1h-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine
EX-A2342
BS-17560
BCP09001
SDCCGSBI-0633803.P001
CCG-270304
C76613
CHEMBL4584341
n,n,n',n' - tetrakis[(6 - methyl - 1h - benzimidazol - 2 - yl)methyl]ethane - 1,2 - diamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1611462Inhibition of BChE (unknown origin) at 5 uM incubated for 10 mins by Ellman's method relative to control2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]